



Oxford, 2<sup>nd</sup> December 2024

**EptivA Therapeutics Ltd. and Infopoly Ltd. today announce an expansion of their strategic alliance, advancing technology to improve the translational development of new medicines for pain and beyond.**

Following the successful development of Pain Cloud<sup>®</sup>, eptivA and digital technology expert Infopoly, announce an extension of their collaboration beyond pain into additional therapeutic areas such as neurology and oncology, with the goal of increasing the odds for new medicines.

Despite all technological advancements, overall drug development costs remain high, whilst clinical trial success rates continue to be low. Current success rates for novel disease targets translating to patient benefit as low as 1% in the case of analgesics. Across many therapeutic areas - including chronic pain, neurology and oncology - the discovery and development of new medicines is often reliant on poorly predictive pre-clinical models. These models might provide valuable insights into disease mechanisms, but there is limited evidence that they validate those mechanism in humans.

Pain Cloud is an integrated network biology platform de-risking the translational development of analgesics for R&D partners. The platform links open access 'large-data' with eptivA's proprietary Pain Landscape<sup>®</sup>, hosting information on over 1,000 distinct pain conditions, to match targets, and medicines to patient populations identifiable; e.g., by phenotype and genotype. Collaborating with Infopoly in 2024, Pain Cloud has been automated to increase its effectiveness in providing unbiased links for research targets to optimised disease phenotypes.

This transformative *in-silico* technology has been validated through *post-hoc* predictions based on approved medicines and those failing at clinical development stage, in addition to successful collaborations with partners, including Bayer Pharmaceuticals. Pain Cloud has the potential to significantly improve the current 1% translational success rate, reducing the time and cost of clinical development.

*"The combination of eptivA's R&D expertise linked with Infopoly's digital software capabilities has enabled the development of the novel Pain Cloud technology. Further integration of our teams will build on this success, taking our proprietary B2B service platform into other therapeutic areas like neurology and oncology."* says Mark J. Field PhD, CEO and Co-founder of EptivA Therapeutics Ltd.; and Dariusz Bielak, CTO of Infopoly Ltd. comments *"By utilising these digital cloud-based solutions, researchers can solve the cost-intensive traditional R&D with a streamlined process to precisely match targets and mechanisms to specific patient groups which saves time and reduces spending."*

For further information, contact Mark J. Field PhD MSc FRSB FIScT, CEO and Co-founder on [mark@eptivatx.com](mailto:mark@eptivatx.com) or Dariusz Bielak CTO and co-founder of Infopoly on [Dariusz.bielak@infopoly.com](mailto:Dariusz.bielak@infopoly.com)